Cerenome, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Marc H. Hedrick
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 6420 Levit Green Blvd Houston TX United States of America 77021
- IPO Date
- Aug 3, 2026
- Website
- plustherapeutics.com
- Similar Companies
- Business
- Plus Therapeutics, Inc. engages in the development of targeted radiopharmaceuticals for the treatment of brain tumors. The company focuses on the research, development, and commercialization of therapies that deliver radiation directly to malignant gliomas and related CNS cancers, leveraging its proprietary drug delivery platforms and radiopharmaceutical products. Main products and services - Therapeutic radiopharmaceuticals for brain tumors; product candidates utilizing targeted alpha-particle and beta-emitting isotopes; development of delivery vehicles and conjugates designed to cross the blood-brain barrier; radiopharmaceutical manufacturing and formulation development; preclinical and clinical testing support; regulatory affairs and regulatory submission support; quality assurance and quality control services for radiopharmaceutical products. - Imaging and diagnostic adjuncts related to CNS oncology; companion diagnostic development and analytic support to identify suitable patient populations. - Research collaborations and sponsored clinical trials; contract research and development services related to radiopharmaceuticals; early-access programs and patient enrollment facilitation for CNS oncology trials. Latest major company changes - Strategic partnerships and collaborations with biopharma and academic institutions to advance clinical development of brain-tumor radiopharmaceuticals; formation or expansion of research alliances to explore combination therapies and novel delivery methods. - Financing activity including recent equity funding rounds and potential strategic investments to support ongoing clinical trials and pipeline expansion; active pursuit of acquisitions or asset-level transactions to augment therapeutic portfolio and platform capabilities. - Product and program milestones include new clinical trial initiations or expansions, regulatory submissions or interactions, and updates on manufacturing scale-up or process development; organizational restructurings or leadership changes aligned with growth and pipeline prioritization. - Operational shifts in the last 1-2 years include scale-up of GMP manufacturing capabilities, expanded clinical site networks for CNS tumor trials, and enhanced regulatory and medical affairs functions to support accelerated development timelines. Additional context - Industry and segments: biotechnology; oncology therapeutics focusing on radiopharmaceuticals for CNS tumors; research and development services; clinical development and regulatory affairs. - Target markets and customers: cancer patients with brain tumors, academic medical centers, contract research organizations, and potential licensing partners or acquirers for late-stage assets. - Geographic operations: activities in the United States with potential collaborations and trial sites across North America; potential international collaboration and regulatory engagement as appropriate to development programs. - Founding year and headquarters: founded in the 2000s; headquarters location and corporate offices in the United States. - Subsidiaries and parent relationships: operates as an independent biotech company with its own pipelines and corporate structure; may engage in strategic partnerships with larger pharmaceutical entities and research institutions.
Company News
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
Cerenome Launches as an Integrated CNS Oncology Company